Normal view MARC view ISBD view

Pd(II)-catalyzed oxidative 1,1-diarylation of terminal olefins. [electronic resource]

By:

Werner, Erik W

Contributor(s):

Producer: 20100907Description: 2848-51 p. digitalISSN:

1523-7052

Subject(s):

Online resources:

Available from publisher's website

In: Organic letters vol. 12

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article; Research Support, N.I.H., Extramural

There are no comments on this title.

to post a comment.

Back to results

1 A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.
by Jacqmin, Philippe
2 Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.
by Schoemaker, Rik
3 A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective.
by Wade, Janet R
4 Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.
by Schoemaker, Rik
5 Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.
by Jacqmin, Philippe
6 Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.
by Schoemaker, Rik
7 Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures.
by Schoemaker, Rik
8 Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
by Snoeck, Eric
9 Pharmacokinetics of ribavirin in patients with hepatitis C virus.
by Wade, Janet R
10 Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
by Patel, Gina
11 Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease.
by Wade, Janet R
12 Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
by Alifrangis, Lene
13 Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.
by Novakovic, Ana M
14 Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma.
by Wilkins, Justin J
15 Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group.
by Bonate, Peter L